DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Prophylaxis Against Metoclopramide-Induced Akathisia

Information source: Pamukkale University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Akathisia

Intervention: midazolam (Drug)

Phase: N/A

Status: Completed

Sponsored by: Pamukkale University

Summary

ABSTRACT Study Objective: To compare the effects of midazolam and diphenhydramine for the prevention of metoclopramide induced akathisia. Methods: This randomized, double-blind and controlled trial aimed to investigate co-administered midazolam versus diphenhydramine in the prophylaxis of metoclopramide induced akathisia. Patients 18 through 65 years of age who presented to the ED with primary or secondary complaints of nausea and/or moderate to severe vascular type headache were eligible for this study. Patients were randomized to one of the fallowing three groups: (1) metoclopramide 10 mg + midazolam 1. 5 mg (2) metoclopramide 10 mg + diphenhydramine 20 mg (3) metoclopramide 10 mg + placebo. Metoclopramide was administered as a 2 minutes bolus infusion. Midazolam, diphenhydramine and normal saline solution administered as a 15 minutes slow infusion. Whole procedure was observed, akathisia and sedation scores and vital changes were recorded.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Primary outcome: akathisia and sedation scores

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients 18 through 65 years of age and 50-90 kg of weight who presented to the ED

with primary or secondary complaints of nausea and/or moderate to severe vascular type headache were eligible for this study. Exclusion Criteria:

- Patients who had liver and renal insufficiency

- Electrolyte imbalance

- Acute respiratory symptoms

- Chronic obstructive pulmonary disease

- Blood pressure less than 90/60 mmHg

- Uncooperative individuals

- Pregnant or lactating

- Pre-existing motor disorder

- Restless legs syndrome-parkinson's disease

- Organic brain disorder, (dementia etc.), epilepsy

- Admitted to the ED due to acute psychiatric symptoms

- Deprived mental status

- Advanced hearing loss

- Malnutrition

- Acute asthma attack

- Serious physical illness, especially glaucoma, prostatic hypertrophy, or cardiac

disease

- Had a contraindication to anticholinergic medications

- Within 3 days of study entry patients who had taken an antiemetic antihistaminic,

antipsychotic, antispasmodic, alpha-blocker, or Ca++2-channel blocker, or within 2 weeks of study entry patients who had taken an antidepressant, barbiturate, benzodiazepine, other sedative/hypnotic, opioid, lithium, or illicit sympathomimetic agent were excluded

Locations and Contacts

Additional Information

Starting date: July 2009
Last updated: January 15, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017